Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CICLESONIDE

All products: general benefit

Other products in the same Health Canada class (R03BA) — coverage varies; not interchangeable

  • Beclomethasone dipropionate (Qvar): general benefit
  • Budesonide (Pulmicort Nebuamp): general benefit, Limited Use 260, 261, 262, 263, 264
  • Fluticasone furoate (Arnuity Ellipta): general benefit
  • Fluticasone (Flovent HFA): general benefit
  • Mometasone furoate (Asmanex Twisthaler): general benefit

Alvesco · DIN 02285606 · 100mcg/Actuation · inhaler, 120 doses

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Alvesco · DIN 02285606 Manufacturer: Covis Pharma B.V.; listing date 2007-06-06 Health Canada: Marketed since 2021-09-09 · brand ALVESCO · ATC R03BA08 CICLESONIDE · form Aerosol (metered-dose) · route Inhalation · ingredients CICLESONIDE 100 MCG/ACT · company Covis pharma gmbh · schedule Prescription
Check this DIN again · Health Canada product record

Alvesco: Formulary list price $56.3880/unit (unit not stated in source; not the patient's cost)

Ministry pays: $56.3880 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77111 · Verify on the e-Formulary ↗ (DIN 02285606)

Source record
DIN 02285606: Alvesco Raw flags: sec3=Y Item: 680400093; group id 706; item number 1743; lccId None; manufacturer id COV Source form: Inh-120 Dose Pk; strength: 100mcg/Actuation Recorded listing: General benefit Source prices (unrounded): $56.3880; ministry $56.3880 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02285606 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77111
Shortage status: resolved shortage (ended 2019-05-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02285606
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (68:04 Corticosteroids) and how they are covered

Matched class: 68:04 Corticosteroids

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, FLUDROCORTISONE ACETATE, FLUTICASONE FUROATE, FLUTICASONE PROPIONATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, MOMETASONE FUROATE, TRIAMCINOLONE ACETONIDE Some products covered without a code (check the product listing): BUDESONIDE, DEXAMETHASONE, DEXAMETHASONE 21-PHOSPHATE, HYDROCORTISONE, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE 68:04 Corticosteroids

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 50mcg/Metered Dose, 100mcg/Metered Dose · Aero Inh-200 Dose Pk

BUDESONIDE

· 12 products · Limited Use, codes 260, 261, 262, 263, 264 (9), General benefit (3) · strengths: 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 100mcg/Metered Dose, 200mcg/Metered Dose, 400mcg/Metered Dose · Inh Susp, Pd Inh-200 Dose Pk

FLUTICASONE FUROATE

· 2 products · General benefit · strengths: 100mcg, 200mcg · Blister Pd Inh-30 Dose Pk

FLUTICASONE PROPIONATE

· 14 products · General benefit · strengths: 50mcg/Metered Dose, 125mcg/Metered Dose, 250mcg/Metered Dose, 55mcg/Actuation, 113mcg/Actuation, 232mcg/Actuation, 250mcg/Blister, 500mcg/Blister · Inh-120 Dose Pk, Pd Inh-60 Dose Pk

MOMETASONE FUROATE

· 3 products · General benefit · strengths: 400mcg/Metered Dose, 200mcg/Metered Dose · Pd Inh-30 Dose Pk, Pd Inh-60 Dose Pk

DEXAMETHASONE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 0.5mg, 4mg · Tab

DEXAMETHASONE 21-PHOSPHATE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 4mg/mL · Inj Sol

FLUDROCORTISONE ACETATE

· 2 products · General benefit · strengths: 0.1mg · Tab

HYDROCORTISONE

· 5 products · General benefit (4), Temporary benefit (1) · strengths: 10mg, 20mg · Tab

METHYLPREDNISOLONE

· 1 products · General benefit · strengths: 4mg · Tab

METHYLPREDNISOLONE ACETATE

· 3 products · General benefit · strengths: 40mg/mL, 80mg/mL, 100mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk

PREDNISOLONE SODIUM PHOSPHATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 6.7mg/5mL · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:04 and 5 more
Full class listing Related classes: 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: steroid-responsive bronchial asthma
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: FLUTICASONE FUROATE FLUTICASONE FUROATE · General benefit 1 INDICATIONS ARNUITY ELLIPTA (fluticasone furoate) is indicated for the once-daily maintenance treatment of steroid-responsive bronchial asthma in patients aged 12 years and older. PM: https://pdf.hres.ca/dpd_pm/00072514.PDF; date September 21, 2015; DIN 02446561; fetched 2026-09-10 Product monograph FLUTICASONE PROPIONATE · Off-Formulary Interchangeable, not an ODB benefit (4), General benefit (14) 1 INDICATIONS FLOVENT (fluticasone propionate) is indicated for:  the prophylactic management of steroid-responsive bronchial asthma in adults and children (12 months of age or older). PM: https://pdf.hres.ca/dpd_pm/00060119.PDF; date March 1, 2021; DIN 02237246; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE ALVESCO (ciclesonide) is indicated for:  prophylactic management of steroid-responsive bronchial asthma in adults, adolescents and children 6 years of age and older. Pediatrics: At present, there is limited data regarding the use of ALVESCO in patients <6 years of age and therefore ALVESCO is not recommended for patients younger than 6 years. Geriatrics (>65 years of age): Based on the pharmacokinetic characteristics obtained in patients older than 65 years of age, dose adjustment is not necessary in elderly patients. https://pdf.hres.ca/dpd_pm/00060608.PDF PM date: March 30, 2021 Source product: ALVESCO; DIN 02285606; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.